loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Rossari Biotech Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Rossari Biotech Ltd. 16 Oct 2025 18:25 PM
Result PDF

Q2FY26 Quarterly Result Announced for Rossari Biotech Ltd.

Specialty Chemicals company Rossari Biotech announced Q2FY26 results

  • Revenue from operations grew 18% to Rs 586.1 crore as compared to Rs 498.4 crore.
  • EBITDA improved by 9% to Rs 71.9 crore from Rs 65.9 crore.
    • EBITDA margin at 12.3% as against 13.2%.
  • PAT increased by 5% to Rs 36.9 crore from Rs 35.3 crore.
  • EPS (Diluted) stood at Rs 6.7 as against Rs 6.4.

Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said: “We delivered healthy revenue growth of 18% YoY in Q2 FY26, led by broad-based volume expansion across our key segments. The HPPC, TSC, and AHN businesses grew by 16%, 21%, and 29% respectively, reflecting the continued strength of our diversified portfolio and the focused execution by our teams.

On the export front, we are proud to have expanded our global operations, with several geographies emerging as key drivers of future growth. We registered a strong performance in our export markets by targeting new customers in both new and existing geographies and increasing our wallet share with our partners. For the quarter, Exports grew by 36% YoY and in H1 it grew by 27%, driven by deeper customer engagement in key international markets. Now exports contribute almost 28% of our overall sales.

While robust volumes supported the top line, profitability remained steady owing to subdued pricing and ongoing investments in seeding new business opportunities. We are confident that as these initiatives begin to contribute to revenues, profitability will improve progressively going forward.

With a diversified product portfolio, agile manufacturing capabilities, new capacity additions and a strong balance sheet, we believe we are well-positioned to capitalize on emerging opportunities and drive healthy growth for the foreseeable future. As a growth-focused Company, we remain committed to innovation, continuously developing tailored solutions that meet the evolving needs of our customers. We are working towards expanding our global footprint through our own manufacturing set up and sales & distribution network overseas. This approach strengthens our confidence in delivering sustainable operational and financial performance while creating long-term value for all our stakeholders.”

Result PDF

Result PDF

Specialty Chemicals company Rossari Biotech announced Q1FY26 results

Q1FY26 Consolidated Financial Highlights:

  • Revenue from operations grew 11% to Rs 543.7 crore as compared to Rs 489.7 crore.
  • EBITDA improved by 4.6% to Rs 67.9 crore from Rs 64.9 crore.
    • EBITDA margin at 12.5% as against 13.3%.
  • PAT reduced by 3.7% to Rs 33.6 crore from Rs 34.9 crore.
  • EPS (Diluted) stood at Rs 6.1 as against Rs 6.3.

Q1FY26 Standalone Financial Highlights:

  • Revenue from operations stood at Rs 365.8 crore as against Rs 300.7 crore, up 21.6%.
  • EBITDA increased by 10.3% to Rs 43.9 crore as against Rs 39.8 crore.
    • EBITDA margin at 12.0% as against 13.2%.
  • PAT higher by 7.8% to Rs 26.2 crore as against Rs 24.3 crore.
  • EPS (Diluted) stood at Rs 4.7 as against Rs 4.4.

Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said: “We delivered a steady performance in Q1FY26, with topline growth driven by strong momentum in our HPPC and AHN segments. Despite a challenging and evolving operating environment, our core businesses continued to demonstrate resilience. Though our export business was lower compared to the last quarter, it has shown healthy growth over the last year. While overall growth remained healthy, we are confident that our continued efficiency initiatives and focused efforts on optimising the product mix will continue to drive growth over the coming quarteRs

The HPPC and AHN divisions achieved a healthy growth of 16% and 12% respectively, reflecting the dedicated efforts of our team in a challenging operating environment. We continue to expand our customer base which is significantly contributing to our growth story. The HPPC segment remained the primary growth driver, supported by deeper market penetration and traction across agrochemicals, personal care, institutional and consumer business.

Our ongoing capacity expansion projects across verticals are progressing in a phased manner, with commissioning scheduled over the coming quarters. These strategic investments are aimed at enhancing manufacturing capabilities, improve supply chain agility, and strengthen our responsiveness to high-growth sectors such as personal care, agrochemicals, oil & gas and pharma. We believe these expansions will play a pivotal role in unlocking meaningful value and driving the next phase of our growth journey.

Looking ahead, we remain committed to execution excellence, customer-led innovation, and sustainable value creation. Supported by a robust balance sheet, a strong R&D foundation, and our ongoing capacity expansion initiatives, we are well-positioned to navigate near-term challenges and deliver consistent, profitable growth for all stakeholders.”

Result PDF

Specialty Chemicals company Rossari Biotech announced Q4FY25 & FY25 results

Q4FY25 Financial Highllights:

  • Revenue from operations grew 22.6% to Rs 579.6 crore as compared to Rs 472.7 crore.
  • EBITDA improved by 9.3% to Rs 69.5 crore from Rs 63.6 crore.
    • EBITDA margin at 12.0% as against 13.5%.
  • PAT increased by 0.9% to Rs 34.4 crore from Rs 34.1 crore.
  • EPS (Diluted) stood at Rs 6.21 as against Rs 6.17.

FY25 Financial Highllights:

  • Revenue from operations stood at Rs 2,080.3 crore as against Rs 1,830.6 crore, up 13.7%.
  • EBITDA increased by 6.1% to Rs 265.1 crore as against Rs 249.8 crore.
    • EBITDA margin at 12.7% as against 13.6%.
  • PAT higher by 4.4% to Rs 136.4 crore as against Rs 130.7 crore.
  • EPS (Diluted) stood at Rs 24.63 as against Rs 23.62.

Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said: “We concluded the year with a steady performance, navigating a soft and evolving operating environment. Revenues grew by ~14% driven by healthy export momentum and resilient volumes across key categories. The HPPC segment remained the primary growth driver, supported by deeper market penetration and strong traction across agrochemicals, personal care, institutional and consumer business. The TSC and AHN segments recorded modest revenue growth, contributing positively to the overall performance. We remain optimistic about their medium-to-long-term potential, supported by ongoing portfolio optimization efforts.

Export markets continued to perform well during the year, validating our strategic investments in global partnerships and differentiated solutions. We are also encouraged by the growing momentum in emerging verticals such as institutional cleaning and B2C businesses, which reflect our ability to build scalable, value-added platforms aligned with evolving customer needs.

We continue to invest in capacity enhancement to strengthen our growth foundation and are pleased to announce an additional capex of Rs 97 crore for expansions at our subsidiaries, Unitop Chemicals and Tristar Intermediates, along with Rs 95 crore at Rossari Biotech. These projects, expected to be commissioned in a phased manner by Q4 FY26, are aimed at supporting growth across our key chemistries, improving operational efficiency, and enhancing supply reliability. Our previously announced expansion projects are progressing well, with commissioning expected by Q2 FY26. With these capacity additions, we are well-positioned to meet growing demand across end-user industries.

Looking ahead, we remain focused on delivering sustainable, profitable growth through sharp execution, customer-centric innovation, and strategic diversification. Supported by a strong balance sheet, an agile business model, and a growing global footprint, we are confident in our ability to maintain healthy growth momentum in the coming years.”

Result PDF

Specialty Chemicals company Rossari Biotech announced Q2FY25 results

  • Revenue from operations grew 3.1% to Rs 498.4 crore as compared to Rs 483.5 crore.
  • EBITDA improved by 3.6% to Rs 65.9 crore from Rs 63.6 crore.
    • EBITDA margin at 13.2% as against 13.1%.
  • PAT increased by 7.3% to Rs 35.3 crore from Rs 32.9 crore.
  • EPS (Diluted) stood at Rs 6.4* as against Rs 6.0*

Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said: “We have reported a steady performance this quarter, reflecting the resilience of our business amidst a dynamic market environment. Our HPPC division continues to demonstrate consistent growth, while the Textile business is still navigating headwinds, with a recovery expected in the next calendar year. AHN Business remained stable during the quarter.

On the export front, we are proud to have expanded our global operations, with several geographies emerging as key drivers of future growth. We registered a strong performance in our export markets by targeting new customers in both new and existing geographies and increasing our wallet share with our partneRs In H1FY25, exports grew by 32%, providing support to overall performance amidst softer domestic growth. While the domestic market is also poised for expansion, we expect exports to outpace domestic growth, further strengthening our position in international markets.

We continue to pioneer intelligent and sustainable solutions across industries, enhancing everyday life through our eco-friendly and technology-driven offerings. Our focus on innovation and customer-centric solutions enables us to stay ahead of industry trends, delivering value through products that are both high in quality and sustainability.

With a diversified product portfolio, agile manufacturing capabilities, and a strong balance sheet, we believe we are well-positioned to capitalize on emerging opportunities and drive healthy growth for the foreseeable future. As a growth-focused Company, we remain committed to innovation, continuously developing tailored solutions that meet the evolving needs of our customers We are working towards expanding our global footprint through our own manufacturing set up and sales & distribution network overseas. This approach strengthens our confidence in delivering sustainable operational and financial performance while creating long-term value for all our stakeholders”

Result PDF

Speciality Chemicals company Rossari Biotech announced Q1FY25 results:

Consolidated:

  • Revenue from operations grew 19.3% to Rs 489.7 crore as compared to Rs 410.6 crore
  • EBITDA improved by 12.5% to Rs 64.9 crore from Rs 57.7 crore
  • EBITDA margin at 13.3% as against 14.1%
  • PAT increased by 19.5% to Rs 34.9 crore from Rs 29.2 crore
  • EPS (Diluted) stood at Rs 6.3 as against Rs 5.3 

Standalone:

  • Revenue from operations stood at Rs 300.7 crore as against Rs 258.3 crore, up 16.4%
  • EBITDA increased by 13.4% to Rs 39.8 crore as against Rs 35.1 crore
  • EBITDA margin at 13.2% as against 13.6%
  • PAT higher by 12.5% to Rs 24.3 crore as against Rs 21.6 crore
  • EPS (Diluted) stood at Rs 4.4 as against Rs 3.9

Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said “We are pleased to report a strong start to the new financial year, with significant Y-o-Y increases in both revenues and profits by 19.3% and 19.4%, respectively. This performance was largely driven by healthy volume growth both in our HPPC and TSC business. AHN business remained stable during the quarter.

The HPPC and TSC divisions achieved a robust growth of 21%, reflecting the dedicated efforts of our team in a challenging operating environment. We continue to expand our customer base which is significantly contributing to our growth story. By targeting customers in both new and existing geographies, we have delivered a strong performance in the international markets during the current quarter. Going forward, we expect exports to be a key growth vertical, further strengthening our position in the global market.

R&D is a cornerstone of our growth and innovation strategy, strengthening Rossari's position as a leading solutions provider in the specialty chemicals sector. Our robust R&D capabilities enable us to meet evolving market needs and offer bespoke solutions, driving growth, creating value, and enhancing our reputation for intelligent and sustainable solutions. While commodity chemicals have benefited from global industry trends in the last few years, we see a promising shift where solution providers and formulators with strong R&D capabilities like Rossari will lead the way in creating sustainable value for all stakeholders going forward.

Despite the macroeconomic challenges, we remain optimistic about the remainder of the year. Our growth strategy continues to focus on broadening our customer base, expanding our geographies and prioritizing higher margin products. Our commitment to R&D, particularly in developing new and innovative products, positions us favourably for delivering healthy operational and financial performance going forward.”

Result PDF

Speciality Chemicals company Rossari Biotech announced consolidated Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue from operations grew 16.3% to Rs 472.7 crore as compared to Rs 406.5 crore
  • EBITDA improved by 16.5% to Rs 63.6 crore from Rs 54.6 crore
    • EBITDA margin at 13.5% as against 13.4%
  • PAT increased by 17.8% to Rs 34.1 crore from Rs 28.9 crore
  • EPS (Diluted) stood at Rs 6.17 as against Rs 5.24

FY24 Financial Highlights:

  • Revenue from operations stood at Rs 1,830.6 crore as against Rs 1,655.9 crore, up 10.5%
  • EBITDA increased by 12% to Rs 249.8 crore as against Rs 223.0 crore
    • EBITDA margin at 13.6% as against 13.5%
  • PAT higher by 21.8% to Rs 130.7 crore as against Rs 107.3 crore
  • EPS (Diluted) stood at Rs 23.62 as against Rs 19.38

Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said “We are pleased to conclude the year on a strong note, with a healthy YoY increase in revenues and profits, standing at 10.5% and 21.8%, respectively. This performance was largely driven by the expansion in our HPPC business. Price softening impacted TSC revenues however volumes have remained steady during the year. AHN performance was lower due to external industry headwinds. We remain optimistic about the recovery of these divisions in the upcoming year.

The HPPC division achieved a robust growth of 18%, underpinning the efforts put in by our team to drive performance in a challenging operating environment. We have notably increased our customer base for key products which led to growth during the year. Additionally, we registered a strong performance in our export markets by targeting new customers in both new and existing geographies, further strengthening our international presence. We also achieved substantial success in our Institutional Cleaning segment, which we expect to be an important growth vertical moving forward. This segment caters to large sectors like airports, railways, hotels, and healthcare, providing a strong base for future expansion.

Our growth strategy remains focused on seeding new verticals within our core chemistries, across our three business divisions. Our focus remains on surfactants, phenoxy series, institutional cleaning, performance chemicals etc. In TSC also, we are looking at tapping newer geographies and markets. Our plan remains to enhance our global footprint with our existing and new products and increase our wallet share with our partneRs

As we move forward, we aim to leverage our R&D expertise and strengthen our position as a leading specialty chemicals manufacturer providing intelligent and sustainable solutions. Our strong balance sheet, expanding capacities & market presence, and diverse portfolio give us a solid foundation to capitalize on opportunities within various key industries. We remain a growth-oriented company and believe this strategy will enable us to create significant value for all our stakeholders in the years to come.”

Result PDF

Specialty Chemicals company Rossari Biotech announced Q3FY24 & 9MFY24 results:

Q3FY24 Highlights

  • Revenue: Rs 463.8 crore, a 19% YoY increase.
  • EBITDA: Rs 63.7 crore, up 18% YoY with an EBITDA margin of 13.7%.
  • PAT: Rs 34.4 crore, showing a substantial increase of 34% YoY.
  • EPS (Diluted): Rs 6.2 per share.

9MFY24 Highlights

  • Revenue: Rs 1,357.8 crore, representing a 9% increase compared to the previous year.
  • EBITDA: Rs 185.0 crore, achieved a 10% growth with an EBITDA margin standing at 13.6%.
  • PAT: Rs 96.6 crore, marking a significant 23% growth compared to the same period last year.
  • EPS (Diluted): Rs 17.5 per share.

Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said, "We are pleased to report yet another strong quarter, with revenues and profits showing a significant YoY increase of 19% and 34%, respectively. This performance is primarily attributed to the healthy growth witnessed in our Home, Personal Care & Performance Chemicals (HPPC) division. The division achieved a robust improvement of 31%, underpinning the efforts put in by our team to drive growth in a challenging operating environment. Despite a subdued performance from the Textile Specialty Chemicals (TSC) due to the industry headwinds and Animal Health and Nutrition (AHN) due to seasonal softness, we are optimistic about recovery in these divisions in the coming quarters.

This quarter, while revenues were marginally lower QoQ, we were able to surpass our last quarter's PAT, setting a new record. On a nine-month basis also, our revenues have grown by 9% while PAT growth has been at a high of 23% Vs previous year.
Our growth strategy remains focused on expanding across all business divisions. Having historically seeded new verticals within our core chemistries, our aim in the coming years is to significantly scale up these ventures. We are particularly focused on areas like specialty surfactants, phenoxy series, institutional cleaning, performance chemicals, etc. Our plan remains to tap into global markets with our existing and new products, spread into newer geographies, and increase our wallet share with existing partners.
The emphasis on R&D remains a pivotal aspect of the Company's growth and innovation strategy. Rossari's position as a premier solutions provider is fortified by its R&D capabilities, which enable us to meet evolving market needs and solidify our role as a sought-after partner for bespoke solutions in the specialty chemicals sector. We are dedicated to leveraging our R&D expertise to drive future growth, create value, and strengthen our reputation as a leading provider of intelligent and sustainable solutions across various industries.

In the face of global challenges in the chemical industry, India is set to emerge as a major hub for chemical manufacturing. With our robust R&D framework, strong financial foundation, expanding manufacturing capacities, and diverse product portfolio, we see significant growth opportunities in both domestic and international markets for all our business verticals. Over the next few years, we are confident that this strategic positioning will lead to strong YoY growth, enabling us to create substantial value for all our stakeholders."

 

 

Result PDF

Specialty Chemical company Rossari Biotech announced Q2FY24 results:

- Rossari Biotech Limited announces highest-ever quarterly performance with revenues of Rs 483.5 crore, up 14% YoY.
- EBITDA stands at Rs. 63.6 crore, showing a growth of 13% YoY.
- PAT increases by 38% YoY, reaching Rs. 32.9 crore.
- EPS (Diluted) for the quarter stands at Rs. 6.0, compared to Rs. 4.3 in the previous year.

Business Operations
- Core divisions, HPPC and TSC, drive strong performance with revenue growth of 21% and 5% respectively.
- AHN division experiences subdued performance due to seasonal softness in demand.
- Expanded facility at Dahej to focus on HPPC products and producing ingredients for subsidiary companies.
- Ethoxylation capacity at Dahej facility of Unitop Chemicals Private Limited to be expanded by 30,000 MTPA to meet growing demand in various industries.

 

 

Result PDF

Specialty chemicals company Rossari Biotech announced Q1FY24 results:

  • Consolidated Q1FY24:
    • Revenue from operations stood at Rs 410.6 crore as against Rs 434.7 crore
    • EBITDA at Rs 57.7 crore as against Rs 57.8 crore
      • EBITDA margin at 14.1% as against 13.3%
    • PAT stood at Rs 29.3 crore as against Rs 28.7 crore
    • EPS (Diluted) stood at Rs 5.28 as against Rs 5.18
  • Standalone Q1FY24:
    • Revenue from operations stood at Rs 258.3 crore as against Rs 233.7 crore
    • EBITDA at Rs 35.1 crore as against Rs 27.1 crore
      • EBITDA margin at 13.6 % as against 11.6%
    • PAT stood at Rs 21.6 crore as against Rs 15.4 crore
    • EPS (Diluted) stood at Rs 3.90 as against Rs 2.78

Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said, “We have recorded a steady performance during the quarter, demonstrating the resilience and adaptability of our business model amidst a challenging global economic landscape. Our commitment to sustainable and innovative solutions has kept us in a stable position despite the current subdued demand scenario witnessed in the chemical markets.

As a part of its digitisation initiatives, the Company during the quarter went live on SAP S/4 HANA across the Group. For this transformation to a new ERP, the Company had taken about a week’s planned shutdown in April and then about another week for system stabilisation. We are happy to inform you that the entire process happened seamlessly and the system is running smoothly. This planned migration resulted in lower sales in April 2023.

We are delighted to share that during the quarter, we acquired the remaining 16% stake in our subsidiary Tristar Intermediates Private Limited and we are nearing the completion of the acquisition of the remaining stake in Unitop, leading to 100% ownership. Following these strategic moves, our intent to seamlessly integrate both Unitop and Tristar into our operations will drive growth, and enhance overall competitiveness.

R&D continues to be a cornerstone of our growth strategy and will play a pivotal role in the Company’s future roadmap. Our confidence in customised products as a differentiator is backed by our track record in developing unique and innovative solutions for our customers As the market landscape continues to evolve, we see our emphasis on R&D and customised solutions as an important pillar in maintaining consistent growth in a volatile environment.

Despite the macroeconomic challenges, we remain optimistic about the remainder of the year. We firmly believe that our strategic initiatives focused on broadening our customer base, prioritizing higher margin segments, along with our commitment to R&D, particularly in developing new and innovative products, position us favourably for delivering healthy operational and financial performance in the coming years."

 

Result PDF

Specialty Chemicals company Rossari Biotech announced Q4FY23 & FY23 results:

  • Consolidated Q4FY23 vs Q3FY23:
    • Revenue from operations stood at Rs 406.5 crore as against Rs 389.3 crore
    • EBITDA at Rs 54.6 crore as against Rs 54.2 crore; EBITDA margin at 13.4% as against 13.9%
    • PAT stood at Rs 29.0 crore as against Rs 25.7 crore
    • EPS (Diluted) stood at Rs 5.2 as against Rs 4.6
  • Consolidated FY23 vs FY22:
    • Revenue from operations stood at Rs 1,655.9 crore as against Rs 1,483.0 crore
    • EBITDA at Rs 223.0 crore as against Rs 183.4 crore; EBITDA margin at 13.5% as against 12.5%
    • PAT stood at Rs 107.3 crore as against Rs 97.7 crore
    • EPS (Diluted) stood at Rs 19.4 as against Rs 17.7
  • Standalone Q4FY23 vs Q3FY23:
    • Revenue from operations stood at Rs 263.6 crore as against Rs 236.9 crore
    • EBITDA at Rs 35.8 crore as against Rs 31.9 crore; EBITDA margin at 13.6% as against 13.5%
    • PAT stood at Rs 23.1 crore as against Rs 17.5 crore
    • EPS (Diluted) stood at Rs 4.2 as against Rs 3.2 

Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said “We are pleased to close the year on a steady note, with revenues increasing by 4.4% on a Q-o-Q basis. While we faced several macro and operational challenges during the year, we believe, we have effectively addressed them and are now positioned to deliver consistent growth going forward. With a focus on cost management, better margin products, and moderation in raw material costs, we were able to improve our Gross and EBITDA margins throughout the year, reaching 29.3% and 13.5%, respectively, as at year ended FY23.

Both our acquisitions Unitop Chemicals Private Limited and Tristar Intermediates Private Limited have added significant value to our portfolio by expanding our market reach, R&D capabilities, operations, business development, and product offerings. We have already experienced significant benefits from the synergies between these companies and our existing business units, impact of which will be further visible over the next few years.

The specialty chemicals industry in India is poised for significant growth in the coming years, driven by as increasing demand for specialized chemicals in various end-use industries and the shift towards sustainability. Overall, our strong financial position, strengthened product portfolio, fungible manufacturing facilities, our focus on constant innovation and green solutions, and other inherent strengths, provide a solid foundation for us to create a healthier and more sustainable future. We remain committed to delivering long-term value to our stakeholders while maintaining our market position as a top provider of intelligent and sustainable solutions. As we continue to evolve and innovate, we remain optimistic about our ability to capitalize on emerging opportunities in the market.

Overall our financial position remains strong. Even after undertaking organic and inorganic expansion over the last few years, our balance sheet profile is healthy. As on March 31, 2023, we continue to be net cash positive with net cash of Rs 77 crores."

 

 

Result PDF

Trending News

Silver price hits new high

As per media sources, silver prices reached an all-time high of $67 per ounce for the first time yesterday.

Published on 22-Dec-2025 09:13

Krishna Institute sets up super speciality hospital

Krishna Institute of Medical Sciences Limited has entered into a lease and licence agreement with Andhra Mahila Sabha to lease around 1.168 acres of land in Chennai for setting up a super speciality hospital. 

Published on 22-Dec-2025 09:12

Delhi cracks down on liquor cartels

According to media reports, Delhi government is cracking down on liquor cartels even as the top selling liquor brands remain the same in the national capital as during the previous Aam Aadmi Party (AAP) regime. 

Published on 22-Dec-2025 09:11

Titan aims for $1 billion watch sales

Titan is optimistic for its watch business, which is expected to touch the $1 billion sales mark in the next two years, led by factors such as premiumisation, retail footprint expansion and growth of the international business division. 

Published on 22-Dec-2025 09:10

Shree Cement gets greenlight for ₹2,000 cr cement plant

As per media reports, Shree Cement has signed an LoI with Maharashtra to set up a 2 mtpa cement plant in Chandrapur district, Maharashtra with an investment of Rs 2000 crore. 

Published on 22-Dec-2025 09:09

US President signs national defense act

The US President has signed the National Defense Authorisation Act, an amended version of the US Biosecure Act. 

Published on 22-Dec-2025 09:08

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status